January 2026 in “Pharmaceutics” New drug delivery systems show promise in effectively treating pathological scars.
January 2026 in “Pharmaceutical Medicine” January 2026 in “Medicina” JAK inhibitors show promise for treating various skin disorders effectively and safely.
November 2025 in “Biomedicines” Targeting pyroptosis may offer new treatments for alopecia areata, but more research is needed.
November 2025 in “British Journal of Dermatology” The guideline recommends personalized treatment for alopecia areata, including new oral medications and psychological support.
November 2025 in “International Journal of Molecular Sciences” PRP shows promise in healing and regeneration but needs standardized protocols for consistent results.
October 2025 in “Skin Health and Disease” Photothermal conditioning of PRP shows promise for improving hair growth but needs more research for confirmation.
September 2025 in “Australasian Journal of Dermatology” New medications could improve treatment for severe alopecia areata in Australia.
September 2025 in “Journal of Clinical Medicine” Elevated granulysin levels may indicate disease activity in vitiligo and alopecia areata.
September 2025 in “International Journal of Molecular Sciences” Deucravacitinib may help treat various immune diseases beyond psoriasis, but more research is needed.
August 2025 in “Journal of Cosmetic Dermatology” Light-based therapy can help regrow hair in different types of hair loss, but more research is needed.
August 2025 in “Biomolecules” CBD may help with skin and hair issues, but more research is needed.
August 2025 in “Biomolecules” Fibroblast growth factors could be a better, safer treatment for hair loss than current options.
June 2025 in “Frontiers in Medicine” Omalizumab may cause temporary hair loss, especially in women aged 18-60.
June 2025 in “Naunyn-Schmiedeberg s Archives of Pharmacology” Herbal remedies may help with hair loss but need more research.
May 2025 in “International Medical Case Reports Journal” Lichen planus pigmentosus may indicate undetected hepatitis C infection.
May 2025 in “International Journal of Trichology” Dutasteride mesotherapy can cause hair loss in some people.
Advancements in diagnostics, treatments, and technology have improved hair loss detection and restoration, with some types being reversible.
April 2025 in “International Journal of Molecular Sciences” New treatments for hair loss show promise with advanced therapies and better targeting.
March 2025 in “JEADV Clinical Practice” People with primary scarring alopecia have higher risks of other health issues like vitamin D deficiency and thyroid disease.
March 2025 in “Journal of Education Health and Sport” Alopecia areata causes hair loss due to immune issues, and while new treatments show promise, no universally effective solution exists yet.
February 2025 in “Cosmetics” Blue light therapy is promising for skin and hair conditions but needs more research for widespread use.
December 2024 in “Archives of Dermatological Research” COVID-19 vaccines do not increase the risk of alopecia areata.
Topical treatments like minoxidil and corticosteroids are effective for hair loss, with JAK inhibitors promising for alopecia areata.
April 2024 in “International journal of molecular sciences” Light-based treatment, Photobiomodulation, shows promise for non-invasive skin therapy with few side effects.
January 2024 in “Dermatologic therapy” Tofacitinib is a safe treatment for hair loss in children, but long-term use may be needed for best results.
November 2023 in “Stem cells and cloning” A new treatment using stem cell-conditioned media significantly improved hair growth in people with temporary hair loss.
Nanocarriers with plant extracts show promise for safe and effective hair growth treatment.
October 2023 in “Biomaterials” Nanotechnology could improve hair regrowth but faces challenges like complexity and safety concerns.
September 2023 in “International Journal of Trichology” Early treatment of Folliculitis Decalvans in children can improve inflammation and partially regrow hair.